Sign In
Buy MGNX
$4.69
+0.110 (+2.40%)
At Close: Jun 23, 2026
MacroGenics Announces Publication of SOPHIA Trial Results for MARGENZA™ in JAMA Oncology
07:30am, Monday, 25'th Jan 2021
ROCKVILLE, MD, Jan. 25, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeut
MacroGenics to Participate in Upcoming Investor Conferences
08:45am, Monday, 11'th Jan 2021
ROCKVILLE, MD, Jan. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therape
MacroGenics Announces MGD019 Publication in Cell Reports Medicine
11:35am, Tuesday, 22'nd Dec 2020
PD-1 × CTLA-4 Bispecific DART® molecule is preliminarily well-tolerated in dose escalation clinical study PD-1 × CTLA-4 Bispecific DART® molecule is preliminarily well-tolerated in dose escalation
MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule
07:30am, Friday, 18'th Dec 2020
ROCKVILLE, MD, Dec. 18, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therape
Why MacroGenics Stock Soared Then Sank Today
03:47pm, Thursday, 17'th Dec 2020
There were different reactions to the company's first FDA approval.
MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
04:30pm, Wednesday, 16'th Dec 2020
ROCKVILLE, MD, Dec. 16, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therape
Steven Cohen Boots Health Care Exposure With 2 Biotech Stocks
05:27pm, Friday, 11'th Dec 2020
Billionaire investor Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm, Point72 Asset Management, established a 14.37% stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) and a 7.96%
ROCKVILLE, MD, Dec. 07, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-ba
MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
01:00pm, Sunday, 06'th Dec 2020
ROCKVILLE, MD, Dec. 06, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-ba
MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab
04:30pm, Monday, 30'th Nov 2020
ROCKVILLE, MD and CHICAGO, IL, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monocl
MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte
07:30am, Monday, 30'th Nov 2020
ROCKVILLE, MD, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-ba
MacroGenics: Q4 PDUFA Target Action Date, 2021 Expected Revenue Growth Of 116%, And $281M In Cash Make It A Buy
10:54am, Friday, 27'th Nov 2020
MacroGenics is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for immune-response modulation for treating cancer. MacroGenics's pipeline consists of 7 the
MacroGenics to Participate in Upcoming Investor Conferences
05:00pm, Monday, 09'th Nov 2020
ROCKVILLE, MD, Nov. 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-b
MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q3 2020 Results - Earnings Call Transcript
12:05am, Friday, 06'th Nov 2020
MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q3 2020 Results - Earnings Call Transcript
MacroGenics Provides Update on Corporate Progress and Third Quarter 2020 Financial Results
04:01pm, Wednesday, 04'th Nov 2020
Conference call scheduled for today at 4:30 p.m. ET. Conference call scheduled for today at 4:30 p.m. ET.
